Follow Slashdot blog updates by subscribing to our blog RSS feed


Forgot your password?
Slashdot Deals: Deal of the Day - Pay What You Want for the Learn to Code Bundle, includes AngularJS, Python, HTML5, Ruby, and more. ×

Submission + - Michael J. Fox Donates $2M USD to a Finnish Medicine Company

jones_supa writes: Biotie Therapies from Turku, Finland has signed a USD 2 million research contract with The Michael J. Fox Foundation (MJFF) to investigate SYN120 in Parkinson's disease patients with dementia. SYN120 is a dual antagonist of 5-HT6 and 5-HT2a receptors and these two distinct modes of action could result in a unique therapeutic profile for SYN120 combining pro-cognitive and antipsychotic activities. MJFF will fund an 80 patient, Phase 2a, randomized, double-blind, placebo-controlled trial of 16 weeks duration in patients with Parkinson's disease dementia. In addition to assessing safety and tolerability, the main focus of the trial will be to establish efficacy of SYN120 on cognition using the Cognitive Drug Research (CDR) Computerized Cognition Battery as the primary efficacy endpoint. This trial, which is expected to begin in H2 2014, will be conducted by the Parkinson Study Group (PSG) at approximately 10 US sites specializing in cognitive dysfunction in Parkinson's disease.
This discussion was created for logged-in users only, but now has been archived. No new comments can be posted.

Michael J. Fox Donates $2M USD to a Finnish Medicine Company

Comments Filter:

"The Avis WIZARD decides if you get to drive a car. Your head won't touch the pillow of a Sheraton unless their computer says it's okay." -- Arthur Miller